RINVOQ LQ vs UPADACITINIB

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Attribute	RINVOQ LQ	UPADACITINIB
Rating	72/100	68/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	UPADACITINIB	UPADACITINIB
Manufacturer	Abbvie	Sandoz
Dosage forms	Solution	Tablet, extended release, Tablet
Drug class	Janus Kinase Inhibitor	Janus Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 8 to 14 hours (mean terminal elimination half-life)	about 8 to 14 hours (mean terminal elimination half-life)
Treats	Rheumatoid Arthritis	Rheumatoid Arthritis

rinvoq lq upadacitinib

Rating

72/100

68/100

Pharmacy pays

—

Type

Active ingredient

UPADACITINIB

Manufacturer

Abbvie

Sandoz

Dosage forms

Solution

Tablet, extended release, Tablet

Drug class

Janus Kinase Inhibitor

Boxed warning

None

Half-life

about 8 to 14 hours (mean terminal elimination half-life)

Treats

Rheumatoid Arthritis

Frequently asked questions

Which is better-rated, Rinvoq Lq or Upadacitinib?

By our independent rating, Rinvoq Lq scores higher — 3.6 vs 3.4 out of 5 for Upadacitinib. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Rinvoq Lq and Upadacitinib?

Both Rinvoq Lq and Upadacitinib share the active ingredient Upadacitinib.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.